EP 166: Developing targeted therapies for ALS with Eric Green from Trace Neuroscience, Maze Therapeutics, and Stanford University

0:00 Intro to The Genetics Podcast
01:00 Welcome to Eric, his background in cardiology, and how he got into biotech
05:20 Eric’s experience incubating and spinning out early-stage companies with Third Rock Ventures and developing Maze Therapeutics
08:10 Eric’s decision to transition from academia to the world of biotech
10:21 Building Maze Therapeutics and Eric’s focus on and genetic modifiers to discover new drugs
14:06 The growth of therapeutic modalities in the context of genetics and gene therapies
15:45 What led Eric to launch Trace Neuroscience and focus on ALS and other neurological disorders
22:10 Eric’s work on the UNC13A gene and bringing new hope to the development of ALS therapies
27:32 The process of getting Trace’s ALS therapies into the clinic
31:19 The identification of therapeutic value in low odds ratio genes
34:55 Eric’s view on the APOA1 gene target and its major effect size in kidney disease
39:00 How best to integrate genetics and genetic discovery into small and medium biotechs
40:47 Closing remarks

Find out moretraceneuro.com